Grant of warrants
May 5,
2022Announcement
no. 10
Grant of warrants
The Board of Directors of BioPorto A/S
(“BioPorto”) (Nasdaq: BIOPOR), in accordance with its current
authorization to issue warrants to key employees of BioPorto, today
issued 270,000 warrants for the subscription of an equal number of
shares.
The warrants are issued in accordance with the
company’s remuneration policy and the authorization in section 18 a
of the Articles of Association.
Each warrant grants the holder the right to
subscribe for one share in BioPorto. The exercise price is DKK 1.28
per share corresponding the closing price today on Nasdaq
Copenhagen. The warrants vest over a four-year period. The warrants
include conditions on claw-back in case of e.g., erroneous
financial information and provisions on accelerated vesting in case
of e.g., a takeover bid and/or business combinations.
Detailed terms of the new and existing warrants,
including applicable vesting schedules, can be found in the
Articles of Association on www.bioporto.com under Investor
Relations> Governance> Company Articles.
The theoretical market value of the newly issued
warrants is DKK 149,000. The calculation is based on the
Black-Scholes formula using an interest rate of 0.50% and the
historical volatility of BioPorto A/S' shares of 27 months
calculated to 75.37%.
For further information, please
contact:
Tim Eriksen, Zenith AdvisoryTelephone +45 4529
0000, e-mail: investor@bioporto.com
About
BioPorto
BioPorto is an in vitro diagnostics company
focused on saving lives and improving the quality of life with
actionable biomarkers – tools designed to help clinicians make
changes in patient management. The Company uses its expertise in
antibodies and assay development, as well as its platform for assay
development, to create a pipeline of novel and compelling products
that focus on conditions where there is significant unmet medical
need, and where the Company’s tests can help improve clinical and
economic outcomes for patients, providers, and the healthcare
ecosystem.
The Company’s flagship product is The NGAL Test,
which has been designed to aid in the risk assessment of Acute
Kidney Injury, a common clinical syndrome that can have severe
consequences, including significant morbidity and mortality if not
identified and treated early. With the aid of The NGAL Test,
physicians can identify patients potentially at risk of AKI more
rapidly than is possible with current standard of care
measurements, enabling earlier intervention and more tailored
patient management strategies.
BioPorto is headquartered in Hellerup, Denmark
and listed on the Nasdaq Copenhagen stock exchange [CPH:BIOPOR]
- 2022 05 05 - Company Announcement no. 10
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Nov 2023 to Nov 2024
